Phage-antibiotic synergy: Cell filamentation is a key driver of successful phage predation.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
09 2023
Historique:
received: 09 12 2022
accepted: 07 08 2023
revised: 25 09 2023
medline: 26 9 2023
pubmed: 13 9 2023
entrez: 13 9 2023
Statut: epublish

Résumé

Phages are promising tools to fight antibiotic-resistant bacteria, and as for now, phage therapy is essentially performed in combination with antibiotics. Interestingly, combined treatments including phages and a wide range of antibiotics lead to an increased bacterial killing, a phenomenon called phage-antibiotic synergy (PAS), suggesting that antibiotic-induced changes in bacterial physiology alter the dynamics of phage propagation. Using single-phage and single-cell techniques, each step of the lytic cycle of phage HK620 was studied in E. coli cultures treated with either ceftazidime, cephalexin or ciprofloxacin, three filamentation-inducing antibiotics. In the presence of sublethal doses of antibiotics, multiple stress tolerance and DNA repair pathways are triggered following activation of the SOS response. One of the most notable effects is the inhibition of bacterial division. As a result, a significant fraction of cells forms filaments that stop dividing but have higher rates of mutagenesis. Antibiotic-induced filaments become easy targets for phages due to their enlarged surface areas, as demonstrated by fluorescence microscopy and flow cytometry techniques. Adsorption, infection and lysis occur more often in filamentous cells compared to regular-sized bacteria. In addition, the reduction in bacterial numbers caused by impaired cell division may account for the faster elimination of bacteria during PAS. We developed a mathematical model to capture the interaction between sublethal doses of antibiotics and exposition to phages. This model shows that the induction of filamentation by sublethal doses of antibiotics can amplify the replication of phages and therefore yield PAS. We also use this model to study the consequences of PAS on the emergence of antibiotic resistance. A significant percentage of hyper-mutagenic filamentous bacteria are effectively killed by phages due to their increased susceptibility to infection. As a result, the addition of even a very low number of bacteriophages produced a strong reduction of the mutagenesis rate of the entire bacterial population. We confirm this prediction experimentally using reporters for bacterial DNA repair. Our work highlights the multiple benefits associated with the combination of sublethal doses of antibiotics with bacteriophages.

Identifiants

pubmed: 37703280
doi: 10.1371/journal.ppat.1011602
pii: PPATHOGENS-D-22-02110
pmc: PMC10519598
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalexin OBN7UDS42Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011602

Informations de copyright

Copyright: © 2023 Bulssico et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pharmacotherapy. 2020 Feb;40(2):153-168
pubmed: 31872889
Cell Rep. 2021 May 25;35(8):109172
pubmed: 34038739
ISME J. 2017 Jan;11(1):237-247
pubmed: 27326545
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14414-9
pubmed: 23940369
Appl Environ Microbiol. 2018 Oct 30;84(22):
pubmed: 30217844
Genetics. 1943 Nov;28(6):491-511
pubmed: 17247100
Virology. 2015 Nov;485:355-62
pubmed: 26331682
Curr Opin Microbiol. 2019 Oct;51:46-50
pubmed: 31226502
Antibiotics (Basel). 2019 Jul 25;8(3):
pubmed: 31349628
Mol Microbiol. 2006 Jul;61(2):383-93
pubmed: 16771843
Front Cell Infect Microbiol. 2019 Feb 18;9:22
pubmed: 30834237
PLoS One. 2017 Jan 11;12(1):e0168615
pubmed: 28076361
Antimicrob Agents Chemother. 2015 May;59(5):2785-90
pubmed: 25733506
Viruses. 2021 Apr 21;13(5):
pubmed: 33919362
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):178-83
pubmed: 25492931
J Biomed Sci. 2022 Mar 30;29(1):23
pubmed: 35354477
Genetics. 1998 Apr;148(4):1539-50
pubmed: 9560373
J Bacteriol. 2016 Aug 25;198(18):2448-57
pubmed: 27381920
PLoS One. 2015 Jul 17;10(7):e0131466
pubmed: 26186207
Glycobiology. 2013 Jan;23(1):59-68
pubmed: 22923442
Infect Immun. 2020 Jun 22;88(7):
pubmed: 32094257
DNA Repair (Amst). 2003 May 13;2(5):593-608
pubmed: 12713816
Antimicrob Agents Chemother. 2021 Mar 1;65(5):
pubmed: 33649110
J Hosp Infect. 2021 Jan;107:114-115
pubmed: 33217492
mBio. 2020 Aug 4;11(4):
pubmed: 32753497
FEMS Microbiol Lett. 1998 Apr 1;161(1):129-33
pubmed: 9561740
Viruses. 2019 Mar 17;11(3):
pubmed: 30884879
Virus Evol. 2020 Aug 25;6(2):veaa060
pubmed: 33365149
Pharmaceuticals (Basel). 2021 Feb 25;14(3):
pubmed: 33668899
Appl Environ Microbiol. 2005 May;71(5):2338-46
pubmed: 15870320
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19039-44
pubmed: 17135349
Mol Cell. 2019 May 16;74(4):785-800.e7
pubmed: 30948267
Antibiotics (Basel). 2022 Jun 22;11(7):
pubmed: 35884092
Cell Host Microbe. 2019 Feb 13;25(2):219-232
pubmed: 30763536
Int J Infect Dis. 2021 Mar;104:250-254
pubmed: 33434666
Nat Commun. 2013;4:1610
pubmed: 23511474
mSystems. 2020 Feb 4;5(1):
pubmed: 32019835
Nat Microbiol. 2016 Jun 20;1(7):16077
pubmed: 27572972
PLoS Pathog. 2023 Sep 13;19(9):e1011602
pubmed: 37703280
BMC Microbiol. 2015 Mar 08;15:63
pubmed: 25888392
J Mol Biol. 2001 Aug 24;311(4):657-79
pubmed: 11518522
Expert Rev Anti Infect Ther. 2018 Mar;16(3):205-218
pubmed: 29402125
Mutagenesis. 1990 Jan;5(1):63-6
pubmed: 2158613
PLoS One. 2007 Aug 29;2(8):e799
pubmed: 17726529
Pharmaceuticals (Basel). 2021 Nov 13;14(11):
pubmed: 34832939
Nat Med. 2019 May;25(5):730-733
pubmed: 31068712
EBioMedicine. 2022 Jun;80:104045
pubmed: 35537278
Viruses. 2021 Dec 02;13(12):
pubmed: 34960683
Elife. 2021 Sep 09;10:
pubmed: 34498586

Auteurs

Julián Bulssico (J)

Laboratoire de Chimie Bactérienne, UMR7283, Centre National de la Recherche Scientifique, Aix-Marseille Université, Marseille, France.

Irina PapukashvilI (I)

Laboratoire de Chimie Bactérienne, UMR7283, Centre National de la Recherche Scientifique, Aix-Marseille Université, Marseille, France.
Faculty of Exact and Natural Sciences, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.

Leon Espinosa (L)

Laboratoire de Chimie Bactérienne, UMR7283, Centre National de la Recherche Scientifique, Aix-Marseille Université, Marseille, France.

Sylvain Gandon (S)

CEFE, CNRS, Univ Montpellier, EPHE, IRD, Montpellier, France.

Mireille Ansaldi (M)

Laboratoire de Chimie Bactérienne, UMR7283, Centre National de la Recherche Scientifique, Aix-Marseille Université, Marseille, France.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH